OTCMKTS:TMED - Trimedyne Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$8.00 0.00 (0.00 %)
(As of 01/18/2019 04:00 PM ET)
Previous Close$8.00
Today's Range$8.00 - $8.00
52-Week Range$2.25 - $13.90
Average Volume124 shs
Market Capitalization$980,000.00
P/E Ratio4.17
Dividend YieldN/A
Trimedyne, Inc. manufactures and sells lasers, and disposable and reusable fiber-optic laser devices for use in the medical field. It offers lasers, fibers, needles, and switch tips for use in orthopedics, urology, ear and nose surgery, throat surgery, gynecology, gastrointestinal surgery, general surgery, and other medical specialties. The company also provides 80 watt and 30 watt holmium lasers, and side firing laser needles to treat herniated or ruptured spinal discs. In addition, it engages in the provision of services, and rental of lasers and other medical equipment to hospitals and surgery centers on a fee-per-case basis. The company operates in Asia, Europe, Latin America, the Middle East, Australia, and internationally. It markets its products through commission sales representatives in the United States and independent distributors internationally. Trimedyne, Inc. was founded in 1980 and is based in Irvine, California.

Receive TMED News and Ratings via Email

Sign-up to receive the latest news and ratings for TMED and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electromedical equipment
SectorComputer and Technology
Current SymbolOTCMKTS:TMED



Sales & Book Value

Annual Sales$5.57 million


Net Income$230,000.00


Market Cap$980,000.00
OptionableNot Optionable

Trimedyne (OTCMKTS:TMED) Frequently Asked Questions

What is Trimedyne's stock symbol?

Trimedyne trades on the OTCMKTS under the ticker symbol "TMED."

How were Trimedyne's earnings last quarter?

Trimedyne, Inc. (OTCMKTS:TMED) issued its quarterly earnings results on Tuesday, February, 20th. The technology company reported $0.70 EPS for the quarter. The technology company earned $1.53 million during the quarter. View Trimedyne's Earnings History.

When is Trimedyne's next earnings date?

Trimedyne is scheduled to release their next quarterly earnings announcement on Tuesday, February 19th 2019. View Earnings Estimates for Trimedyne.

Has Trimedyne been receiving favorable news coverage?

News headlines about TMED stock have trended somewhat positive on Saturday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Trimedyne earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned news articles about the technology company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an impact on the stock's share price in the near future.

Who are some of Trimedyne's key competitors?

Who are Trimedyne's key executives?

Trimedyne's management team includes the folowing people:
  • Mr. Marvin P. Loeb, Chairman, CEO, Pres, Principal Financial Officer & Chief Scientific Officer (Age 92)
  • Mr. Brian T. Kenney, VP of Global Sales & Marketing (Age 62)
  • Dr. Robert S. Cowles III, M.D., Medical Director

How do I buy shares of Trimedyne?

Shares of TMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Trimedyne's stock price today?

One share of TMED stock can currently be purchased for approximately $8.00.

How big of a company is Trimedyne?

Trimedyne has a market capitalization of $980,000.00 and generates $5.57 million in revenue each year.

What is Trimedyne's official website?

The official website for Trimedyne is http://www.trimedyne.com.

How can I contact Trimedyne?

Trimedyne's mailing address is 5 HOLLAND BLDG #223, IRVINE CA, 92618. The technology company can be reached via phone at 949-951-3800.

MarketBeat Community Rating for Trimedyne (OTCMKTS TMED)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  33 (Vote Outperform)
Underperform Votes:  57 (Vote Underperform)
Total Votes:  90
MarketBeat's community ratings are surveys of what our community members think about Trimedyne and other stocks. Vote "Outperform" if you believe TMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel